A single center, open-label, dose-escalating, Phase I study to evaluate the safety of GX-188E administered by electroporation (EP) in DNA-based therapeutic vaccine for patients with Cervical Intraepithelial Neoplasia grade 3 (CIN 3)

Trial Profile

A single center, open-label, dose-escalating, Phase I study to evaluate the safety of GX-188E administered by electroporation (EP) in DNA-based therapeutic vaccine for patients with Cervical Intraepithelial Neoplasia grade 3 (CIN 3)

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2014

At a glance

  • Drugs GX 188E (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 10 Mar 2014 Status changed from recruiting to completed, as per Korean Clinical Trials Register record.
    • 13 Feb 2013 New source identified and integrated (KCT0000586: Clinical Research Information Service (CriS) - Republic of Korea).
    • 12 Nov 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top